Thyroid and Cardiovascular Risk: What Matters at Every Level of TSH

Both untreated hypothyroidism and over-replacement (suppressed TSH) raise cardiovascular risk. The lowest risk sits in the middle of the normal range. Atrial fibrillation, heart failure, and coronary heart disease mortality all track thyroid status — including subclinical and over-replaced states.

Why thyroid status drives cardiovascular risk

T3 — the active thyroid hormone — acts directly on cardiac myocytes and vascular smooth muscle. It increases the speed of cardiac contraction (positive inotropy), the rate of relaxation (positive lusitropy), and resting heart rate. It also lowers systemic vascular resistance by relaxing arterial smooth muscle [C3][C5]. When T3 falls in hypothyroidism, the heart contracts and relaxes more slowly, vascular resistance rises, blood pressure tends up, and LDL cholesterol clearance through the LDL receptor slows — which is why total and LDL cholesterol typically rise in untreated hypothyroidism [C1][C3].

The opposite happens when T3 is high (overt or subclinical hyperthyroidism, or in patients over-replaced on levothyroxine): heart rate climbs, the atrium becomes electrically irritable, and bone turnover accelerates. The same hormone that protects the cardiovascular system at physiologic levels destabilizes it at supraphysiologic levels [C4][C6][C7].

This is why "more thyroid hormone" is not a benign strategy. The U-shaped risk curve — higher cardiovascular events at both low T3 and high T3 — is one of the most consistent findings across large prospective cohorts [C3][C4][C5].

What happens at high TSH (under-treatment or untreated hypothyroidism)

Overt hypothyroidism (TSH well above range, low free T4) is associated with diastolic dysfunction, reduced exercise tolerance, and raised LDL [C1][C3]. Subclinical hypothyroidism is more nuanced — the larger the TSH elevation, the more the cardiovascular signal appears [C3][C5]:

• Coronary heart disease and CHD mortality. A 2010 individual-participant-data meta-analysis of 11 prospective cohorts found that the risk of CHD events and CHD mortality rose significantly when TSH was >10 mIU/L, with smaller and less consistent signals between 7 and 9.9 mIU/L [C3].
• Heart failure. A 2012 individual-participant-data analysis from 6 cohorts (over 25,000 participants) showed an increased risk of heart failure events when TSH was >10 mIU/L [C5].
• Lipids. LDL cholesterol usually drops modestly after starting levothyroxine for overt hypothyroidism; the change is smaller and less consistent in mild subclinical hypothyroidism [C1].

The clinical question — whether treating mild subclinical hypothyroidism (TSH 4.6–10) prevents cardiovascular events — was tested directly. See the trials section below.

What happens at low TSH (over-replacement or subclinical hyperthyroidism)

Suppressed TSH — whether endogenous (Graves', autonomously functioning nodule) or iatrogenic (too much levothyroxine) — carries its own cardiovascular signal [C4][C6][C7]:

• Atrial fibrillation. A Danish population cohort (>500,000 adults) found that even mildly suppressed TSH was associated with a higher rate of new-onset atrial fibrillation, with the strongest signal at TSH <0.1 mIU/L [C6]. The Baskaran 2026 systematic review confirmed that levothyroxine over-replacement is independently associated with AFib risk [C8].
• Coronary heart disease mortality. The 2012 IPD meta-analysis of 10 cohorts found that subclinical hyperthyroidism (TSH <0.45 mIU/L) was associated with increased CHD events and CHD mortality, with stronger effects when TSH was fully suppressed (<0.1 mIU/L) [C4].
• Heart failure. The same Gencer 2012 IPD analysis found that subclinical hyperthyroidism was also associated with heart failure events [C5].
• Osteoporosis and fracture risk. Suppressed TSH accelerates bone turnover; this is included here because the Baskaran systematic review treats musculoskeletal and cardiac risks as a single over-replacement syndrome [C8].

The pattern: TSH that is fully suppressed (<0.1 mIU/L) carries the clearest signal for AFib, CHD mortality, and heart failure. Mildly suppressed TSH (0.1–0.4 mIU/L) carries a smaller but still measurable signal [C4][C6][C7].

What the trials actually show

Two questions dominate the trial literature: (1) Does treating mild subclinical hypothyroidism prevent cardiovascular events? (2) Does treating subclinical hyperthyroidism prevent them?

TRUST trial (Stott 2017, NEJM). 737 adults aged 65+ with persistent subclinical hypothyroidism (TSH 4.6–19.9 mIU/L, mean 6.4) were randomized to levothyroxine or placebo for a median of 18 months. The trial found no benefit on hypothyroid symptoms, tiredness, or quality of life. Cardiovascular endpoints were not the primary outcome, but the trial reported no signal of benefit [C2]. This is why current guidelines do not recommend universal treatment for mild subclinical hypothyroidism in older adults — the trial evidence does not support it [C1][C2].

Subclinical hyperthyroidism. No large randomized trial has shown that treating mild subclinical hyperthyroidism reduces cardiovascular events. The 2015 ETA guideline recommends treatment for persistent TSH <0.1 mIU/L in adults >65 or with cardiovascular disease, osteoporosis, or symptoms — driven by the consistent observational signal, not RCT evidence [C7].

Over-replacement on levothyroxine. The Baskaran 2026 systematic review pulled together cardiac, neuropsychiatric, and musculoskeletal harms of over-replacement — confirming that the safest TSH on levothyroxine sits in the middle of the normal range, not at the lower edge [C8].

What does NOT help

• "Optimizing TSH near zero." Some online communities advocate pushing TSH to the lowest end of normal (or below) to feel more energetic. The observational data are consistent that suppressed TSH increases AFib, CHD mortality, and HF risk [C4][C6][C7][C8]. Feeling slightly more energetic at suppressed TSH is not worth the cardiovascular trade-off.
• Routine T3 addition for cardiovascular benefit. Combination T3/T4 trials have not shown cardiovascular benefit over levothyroxine alone in the general hypothyroid population [C1]. See our liothyronine-t3-only article.
• Treating TPO antibody titers without thyroid dysfunction. Anti-TPO positivity alone, with normal TSH, does not require levothyroxine [C1].
• High-dose iodine, kelp, or "thyroid support" supplements. No evidence for cardiovascular protection, and iodine can destabilize Hashimoto's [C1].

Practical guidelines

1. Aim for TSH in the middle of the normal range on levothyroxine — roughly 0.5–2.5 mIU/L for most patients without thyroid cancer. This is where the cardiovascular risk curve is lowest [C1][C3][C4][C8].
2. Avoid persistent TSH suppression unless your endocrinologist has a specific indication (e.g. thyroid cancer follow-up). Suppressed TSH is associated with AFib and CHD events [C4][C6][C7].
3. Re-check TSH 6–8 weeks after any dose change, then every 6–12 months once stable [C1].
4. Ask for a baseline ECG and lipid panel at diagnosis. An LDL above goal often improves on adequate levothyroxine in overt hypothyroidism [C1].
5. Flag palpitations or new irregular pulse to your endocrinologist — these can be the first sign of over-replacement or new AFib [C6][C8].
6. Treat the obvious comorbidities — hypertension, lipid management, smoking cessation. Thyroid status is one input into cardiovascular risk, not the only one.

Frequently asked questions

Should I treat my subclinical hypothyroidism to protect my heart? For mild subclinical hypothyroidism (TSH 4.5–10) in older adults, the TRUST trial showed no benefit on symptoms or events [C2]. For persistent TSH >10 mIU/L, the meta-analytic data support treatment [C3][C5]. Your endocrinologist will weigh age, TSH value, antibody status, and comorbidities [C1].

Is suppressed TSH dangerous even if I feel fine? The observational signal for AFib, CHD mortality, and heart failure is consistent at TSH <0.1 mIU/L — the harm accumulates silently [C4][C6][C7]. Feeling fine doesn't rule it out.

Will levothyroxine fix my high LDL? LDL usually drops after starting levothyroxine for overt hypothyroidism. The change is smaller in subclinical hypothyroidism. Adequate dosing is the first step; statins are added based on standard CV risk calculation [C1][C3].

Does atrial fibrillation go away if I lower my dose? Rate and rhythm can normalize once TSH returns to range, but established AFib often persists and needs its own management (anticoagulation, rate or rhythm control) [C6][C8]. Catching the dose problem early is the lever.

Is T3-only therapy safer for my heart? No. T3-only therapy produces large swings in serum T3 and has been associated with cardiac side effects in long-term users; the ATA does not recommend it as standard therapy [C1][C8]. See liothyronine-t3-only.

Bottom line

Thyroid status is a real, modifiable cardiovascular input. Untreated hypothyroidism — especially TSH >10 mIU/L — increases CHD and heart failure risk [C3][C5]. Over-replacement — especially TSH <0.1 mIU/L — increases atrial fibrillation, CHD mortality, and heart failure [C4][C6][C7][C8]. The lowest-risk zone is the middle of the normal range, which is also the zone the ATA targets for most patients on levothyroxine [C1]. The TRUST trial confirmed that treating mild subclinical hypothyroidism in older adults does not reliably help; the decision is individualized [C2]. Talk to your endocrinologist about your TSH target — especially if you have known cardiovascular disease, AFib risk, or osteoporosis.

Sources

1. [C1] Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism. Thyroid. 2014;24(12):1670–1751. PubMed: 25266247
2. [C2] Stott DJ, Rodondi N, Kearney PM, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017;376(26):2534–2544. PubMed: 28402245
3. [C3] Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–1374. PubMed: 20858880
4. [C4] Collet TH, Gussekloo J, Bauer DC, et al. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799–809. PubMed: 22529182
5. [C5] Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–1049. PubMed: 22821943
6. [C6] Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895. PubMed: 23186910
7. [C7] Biondi B, Bartalena L, Cooper DS, et al. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J. 2015;4(3):149–163. PubMed: 26558232
8. [C8] Baskaran BS et al. Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review. 2026. PubMed: 41559017

---

For educational purposes only. Not medical advice. Always consult your healthcare provider.